Akt Phosphorylation of Deleted in Liver Cancer 1 Abrogates Its Suppression of Liver Cancer Tumorigenesis and Metastasis-Reference-Cited by-同舟云学术

Akt Phosphorylation of Deleted in Liver Cancer 1 Abrogates Its Suppression of Liver Cancer Tumorigenesis and Metastasis

Published:2010-10 Issue:4 Volume:139 Page:1397-1407.e6
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Ko Frankie Chi Fat,Chan Lo–Kong,Tung Edmund Kwok–Kwan,Lowe Scott W.,Ng Irene Oi–Lin,Yam Judy Wai Ping

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference37 articles.

1. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP;Yuan;Cancer Res,1998

2. DLC-1:a Rho GTPase-activating protein and tumour suppressor;Durkin;J Cell Mol Med,2007

3. DLC1: a significant GAP in the cancer genome;Lahoz;Genes Dev,2008

4. Deleted in liver cancer 1 (DLC1) utilizes a previously undocumented binding site for tensin2 PTB domain interaction and required for tumor suppressive function;Chan;PLoS ONE,2009

5. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1;Liao;J Cell Biol,2007

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DLC1 promotes mechanotransductive feedback for YAP via RhoGAP-mediated focal adhesion turnover;Journal of Cell Science;2024-04-15

2. Chromosome 8p engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer;Science Advances;2023-12-22

3. Chimera and Tandem-Repeat Type Galectins: The New Targets for Cancer Immunotherapy;Biomolecules;2023-05-29

4. SH3 domain regulation of RhoGAP activity: Crosstalk between p120RasGAP and DLC1 RhoGAP;Nature Communications;2022-08-15

5. Hinokiflavone Inhibits Growth of Esophageal Squamous Cancer By Inducing Apoptosis via Regulation of the PI3K/AKT/mTOR Signaling Pathway;Frontiers in Oncology;2022-02-01